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Summary
Introduction: In a paper published by Hepler, it is mentioned that the Pharmaceutical 
Care constitutes a change in the paradigm of the profession, an affirmation that it 
is necessary to clarify since apparently, this concept is not used from the philosophy 
or the social sciences. Methodology: A scoping study was performed from system-
atics reviews of literature and meta-analysis published in MEDLINE, EMBASE and 
LILACS, which the role of the pharmacist in the different settings of health care 
was studied. It was not restricted by language or date of publication. Results: The 
selection process identifies 86 reviews published between 1998 and 2014, of which 
84.9% are Systematic Review (SR). It was studied all care settings 23.3%, commu-
nity 22.1%, and ambulatory setting 22.1%. According to the title, 65% referring to 
the role of the pharmacist, 21% with pharmaceutical care or other related terms and 
14% with clinical pharmacy services. There is no uniformity in the concepts of phar-
maceutical care or drugs related problems. Conclusions: It is necessary to construct 
the knowledge object of pharmaceutical care activities from a paradigm that allows 
another understanding of pharmacist interventions, construct values in the patient-
pharmacist relationship supported in Latin American bioethics and a methodology 
of research that transcends the findings of the performed studies using the designs 
of classical epidemiology.
Key words: Pharmaceutical care, pharmaceutical services, drug related problems, 
systematic review.
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Resumen
Hacia una transformación del paradigma del farmacéutico 
asistencial: una revisión de alcance
Introducción: en un artículo publicado por Hepler, se menciona que la atención 
farmacéutica constituye un cambio en el paradigma de la profesión, afirmación que es 
necesario aclarar, ya que, aparentemente, este concepto no se utiliza desde la filosofía 
o las ciencias sociales. Metodología: se realizó un estudio de alcance a partir de revi-
siones sistemáticas de literatura y metanálisis publicadas en MEDLINE, EMBASE y 
LILACS, en las que se estudió el papel del farmacéutico en los diferentes contextos 
de atención de la salud. No se restringió por el idioma o fecha de publicación. Resul-
tados: el proceso de selección identificó 86 revisiones publicadas entre 1998 y 2014, 
de las cuales el 84,9% son revisiones sistemáticas. Se estudiaron todos los ámbitos de 
atención en el 23,3%, comunitario 22,1% y ambulatorio 22,1%. Según el título, el 
65% se refiere al papel del farmacéutico, el 21% con atención farmacéutica u otros 
términos relacionados y el 14% con los servicios de farmacia clínica. No se evidencia 
uniformidad en los conceptos de atención farmacéutica ni problemas relacionados 
con medicamentos. Conclusiones: es necesario construir el objeto de conocimiento 
de las actividades de atención farmacéutica a partir de un paradigma que permita 
otra comprensión de las intervenciones farmacéuticas, construir valores en la rela-
ción paciente-farmacéutico apoyada en la bioética latinoamericana y una metodo-
logía de investigación que trascienda los hallazgos de los estudios realizados desde la 
epidemiología clásica.
Palabras clave: atención farmacéutica, servicios farmacéuticos, problemas relacio-
nados con medicamentos, revisión sistemática.
Introduction
The activities of the pharmacist have introduced a significant change since the 1990s, 
which has been described by Hepler as a change in the paradigm of the profession. 
However, it must be clarified that this implies a different conception of the health-
disease concept, the drug, and the process itself of pharmaceutical care.
The main activity of the new professional pharmacist was the artisanal manufacture 
and personalized distribution of the medicine in the seventeenth century. This situ-
ation remained until the end of the 19th century when the industrialization processes 
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reached the field of medicine, and the pharmacist had to leave the apothecary aside 
to make way for the pharmacy-drugstore. In the middle of the 20th century, due to a 
series of political, social, and economic facts, the professional pharmacist faces a differ-
ent relationship with people who use medicines, which we will call in this document 
“Pharmaceutical Care Activities (PCA).” The reason for the shift in the relationship 
was the pharmacist’s role: in the pharmaceutical industry to design new pharmaceuti-
cal forms, production, quality control of medicines, and in the community pharmacy 
to the distribution, procurement, and dispensing of medications [1-3]. This relation-
ship was born, at least in part, with the aim of controlling and reducing the medicine’s 
toxic effects and improving their effectiveness when their production and availabil-
ity in the market increased. Although it was initially insisted that this constituted a 
commitment and a responsibility of the pharmacist with the patient to maximize the 
chances of therapeutic success with minimal adverse effects; the economic background 
in this undertaking is perceived as such [4, 5].
Hepler attributes a change to this new activity in the paradigm of the profession. An 
affirmation that is necessary to clarify since this concept acquires different meanings, 
for example, for Plato the paradigm is a case of the model or the rule; for Aristotle, is 
the argument that is destined to be generalized; for Kuhn, they are the models that 
establish the form in which the scientific investigation is realized, these models are 
constituted by laws, theories, application, and tools necessary for their demonstration; 
for Morín, it is “... a mental and cultural structure which one looks at the reality, and 
because of being cultural, are unconscious”; and finally, for the Social Sciences, it con-
sists of a “set of opinions and beliefs that make up the general image or concept of the 
world that a person, time, or culture has, from which a person interprets its nature and 
everything that exists” (world’s view). In any case, every paradigm contains hidden a 
small nucleus of postulates and principles of knowledge; which rules and controls the 
entire cognitive field of reference, and constitutes the set of beliefs, imaginaries, dis-
cursive practices, concepts, ideas, recognized values, techniques, and truth criteria of a 
community [6-9].
For the development of PCAs, the concepts of ‘health’ and ‘health care’ must be taken 
into account. In one hand, it is necessary to clarify that ‘health’ is not the antagonist 
of illness and it is rather constituted of a relational matter that affects the daily life of 
social groups, and it is part of a process in which subjectivity is constructed collectively. 
The social response to the disease (care) is also a common and frequent fact that con-
tributes to the formation of an essential structure for the production and reproduction 
of society [10, 11]. The disease and the response that it originates are fundamental 
processes in all social systems and groups that produce representations and practices, 
and constitute a piece of knowledge that allows them to understand, confront, solve 
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and, in many cases, pretend to eliminate diseases. For that reason in the social medicine 
field the term, Health-Disease-Care process is used since these events cannot be dis-
connected [12, 13]. Concerning the care process for our case, it is composed of drugs 
and pharmaceutical care (PC). For the first, drugs are considered a chemotherapeutic 
agent that presents an ontological dichotomy (merchandise and symbol) that is stud-
ied from different perspectives: experimental pharmacology, clinical trials, pharmaco-
epidemiology, and pharmaceutical technology, among others. About PC, it has been 
established as the paradigm (according to Plato and Aristotle) of PCA. The concept 
was proposed in 1990 by Hepler [4], in the United States from a term used by Mikeal 
et al. in 1975 as an approximation of the definition analogous to medical care, then it 
was spread to Europe and Latin America, and since that moment, it has been subject to 
changes and proposals, mainly methodological ones. Both the health-disease concept 
and the care activities have undergone transformations throughout the human history 
depending on the current paradigm.
It is proposed to reflect on the paradigmatic basis, concept, approaches, and method-
ology of the PCA to contribute to the construction of the knowledge object in a dif-
ferent way that recognizes and stimulates the existence and manifestations of diverse 
perspectives, to understand and to debate them, for which the following elements are 
required: 1) To recognize and identify the person as an individual immersed in com-
plex social relationships that make him/her more than the sum of cells, tissues, organs, 
and systems, 2) To use the term cuidado (“care” in Spanish) that includes many other 
aspects such as commitment, responsibility, and needs assessments that left out in the 
term atención (current translation into Spanish of the word “care”), 3) To construct 
the drug related problems (DRP) from the perspective of social medicine and taking 
into account the priority of the patient’s needs according to the proposal of Maslow, 
and 4) To propose the use of social epidemiology and other qualitative methodological 
approaches (participatory action research, for example) for research and professional 
practice that allow individual and collective interventions from the social paradigm.
Methodology
Design: a scoping study was carried out using tools of the Reviews of Reviews. 
Question for the review: what are the approaches, methodologies, and results obtained 
in the different systematic reviews and meta-analyses on PCAs?
Inclusion and Exclusion Criteria: papers that had a SR or Meta-Analysis (MA) as 
a research design, which was already published at the time of the search, and that 
described or evaluated the PCA in any setting (community, ambulatory or hospital) 
Towards a transformation in the pharmacist care paradigm: A scoping study
375
were included. The papers were classified as SR if it includes at least the following char-
acteristics: a described search strategy, the use of at least two databases, and selection 
of papers in pairs. Those studies in which the pharmacist’s intervention was not suf-
ficiently clear in the full text or that has been carried out by pharmacy students were 
excluded since it is intended to identify the PCA from a professional performance 
perspective and not from the academic standpoint.
Information Sources: the MEDLINE, EMBASE, LILACS databases were used. 
Besides, the papers cited in the articles obtained to detect more relevant articles, and in 
turn, the references of those articles were reviewed until that strategy was exhausted. It 
was used the bibliographic material the authors had and was found in publications that 
are unique to the topic in the following journals: Research in Social and Administrative 
Pharmacy, Pharm Care Esp, American Journal of Health-System Pharmacy, American 
Journal of Hospital Pharmacy.
The searching strategy included:
MEDLINE: (Pharmaceutical services [MeSH] OR “Pharmaceutical care” [tw] OR 
“Drug Therapy Management” [tw]) AND (“Systematic review” [tw] OR “Meta-anal-
ysis” [tw]).
EMBASE: ‘pharmaceutical services’ / exp OR ‘pharmaceutical services’ OR ‘commu-
nity pharmacy services’ / exp OR ‘community pharmacy services’ OR ‘pharmacy ser-
vice, hospital’ / exp OR ‘pharmacy service, hospital’ AND (systematic review ‘AND’ 
systematic review (topic) ‘/ OR’ meta-analysis’).
LILACS (“pharmaceuticalcare” OR “atención farmacéutica”) OR “pharmaceuticalser-
vices” OR “servicios farmacéuticos”. Limited to systematic reviews and meta-analyses.
Studies Selection: two reviewers independently pre-selected the references by titles 
and abstracts, and then, the pre-selected reviews were evaluated with the full text. If 
the study did not meet all the inclusion criteria or if it had any exclusion criteria; it 
was classified as an ‘excluded study,’ justifying the reason for disqualification. Disagree-
ments between the reviewers were solved after discussion with the authors, and in any 
case, an external evaluator was required.
Data collection: data were extracted from published studies using a pre-piloted Micro-
soft Excel® format, initially based on the variables contained in the Data Collection 
Checklist of the Cochrane Effective Practice and Organization of Care Review Group 
(EPOC), which was refined, based on the work objectives and the reference frame-
work presented. The extraction of data from each article was carried out by three inde-
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pendent reviewers (including the authors), who resolved their disagreements through 
the author’s participation in the review of reviews.
Results and discussion
This section presents a general description of the type of review, the settings of care, 
and the terminology used in the title to describe care activity. Subsequently, the results 
of the approach are presented, then the construction of the knowledge object and 
finally the methodology used.
Scoping studies offers a good alternative since they are used when a literature volume 
has not yet been extensively reviewed or exhibits a large, complex, or heterogeneous 
nature that is not amenable to a more accurate systematic review [18, 19]. Other 
designs were not adequate to perform our review [14-17].
Figure 1 describes the selection process where 86 reviews published between 1998 and 
2014 were finally included; of which 73 (84.9%) were SR and 13 (15.1%) were MA. 
These SR/MA studied all care settings (n = 34, 39.5%), community (n = 19, 22.1%), 
ambulatory setting (n = 19, 22.1%), and hospitality setting (n= 14, 16.3%). Care set-
ting refers to the place where the practitioners perform their activities. Thus, ambula-
tory setting is outside of hospitals, hospitality setting is in the hospital and community 
setting refers to the neighborhood pharmacy. According to the title, 7 reviews were 
recovered with pharmaceutical care, 4 with pharmacist care, 56 referring to the role of 
the pharmacist (29 explicitly mentioned the intervention), 8 with clinical pharmacy 
services, 4 with pharmaceutical/pharmacist/pharmacy service, 3 with medication review, 
2 with medication management, 1 with pharmacotherapeutical follow-up, and another 
with pharmaceutical patient assistance programs.
PCAs approaches 
Due to the concept of approach can be interpreted in several ways; this review will 
consider: first, the used definition of PCA, and second, the ideology of care. Regarding 
the definition of PCA, it was take into account whether it is used some term related to 
PCAs (PC, clinical pharmacy, pharmacotherapeutic follow-up, etc.), and second, if the 
approach used the ideology of care proposed by Bjorkman Bernsten and Sanner [20], 
which identified patient-centered care (PCC) and evidence-based medicine (EBM) 
as the basis of four recognized methodologies: Strand, Granada, Pharmaceutical Care 
Network European (PCNE), and Apoteket. Since this ideology as such is not described 
in any review, it was searched its presence in the SR/MA of some of the methodologies 
mentioned above. This analysis found that in 31.4% (27/86) of all selected reviews, 
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some of the concepts previously described were mentioned. The 17.4% (15/86) of 
the reviews were identified using the Hepler/Strand/Cipolle methodology (unique 
to the PCC approach), and 3.5% (3/86) with the Granada methodology which was 
discussed with that of Hepler and Strand. Other practices such as Clinical Pharmacy, 
Pharmaceutical Assistance, and Medication Management were present in 5.8% (7/86) 
of the publications, while in 2.3% (2/86) the term PC was mentioned, but there was 
no methodology the authors of the review are identified with.
As in the reviews by Melchiors et al. and Kennie et al. [21, 22], it is identified the misuse 
of the term PC, the incorrect indexing, lack of definition in the study methodology, 
and some reviews only describe patient counseling, clinical pharmacokinetic services, 
and review of the medication use. Occasionally it could be thought that the justifica-












Title/abstract: No described or
evaluated the PCA in any setting
N = 38
Rese arch design was not SR/MA
N = 983
No available full text
N = 8
Figure 1. Scheme of inclusion and exclusion criteria of studies.
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tion for their presence in the health team is rather sought, as mentioned by Oliveira et 
al. [23]. This disagreement with the term PC may be related to the following aspects:
– According to Hepler [24], the concept of PC stimulates the pharmacists’ imagi-
nation, causing the pharmacist to emphasize more some ideas than others and 
forgetting that medication therapy cannot be provided without the collabora-
tion of the patient and other health professionals. Its evidence is that Van Mil 
and Fernandez-Llimos [25], Machuca et al. [26], Blackburn et al. [27], Alina 
Martínez [28], have debated the PC concept, and recently, Allemann et al. [29] 
performed a review of the PC’s definitions found in the literature, in order to 
construct one that includes all existing ones.
– Cipolle et al. [30] mention that it is possible that the differences in the concep-
tion of the term PC are related to the cultural characteristics, higher education 
training centers, and health systems of each country.
– Although PC is accepted by most pharmacists, precise information is needed on 
the roles and responsibilities that pharmacists assume in providing this service. 
In published studies, the adopted definition or the title does not always coincide 
with the concept and philosophy of the practice, defined by Hepler and Strand. 
Although, it could be thought that they perform similar methods [21, 22, 31].
– Several authors [20, 32, 33] have mentioned that the pharmacist possesses knowl-
edge that no other professional has; and the difference in the terms that describe 
the PCAs is in its application and who benefits from that knowledge: if it is the 
group of health professionals, it is called a clinical pharmacy; if it is the patient, 
it is called PC; if it is the community health, it could be the pharmacy cognitive 
services.
– Van Mil and Fernandez [25] claim that there is also a problem in the translation 
into Spanish of the term ‘pharmaceutical’. Since ‘pharmaceutical’ is associated 
with the field of medicine design and development, while ‘pharmacist’ refers to 
the professional and includes activities related to the prevention and promotion 
of health from the field of medicines; they propose to use the term Cuidado del 
Farmacéutico in exchange for Atención Farmacéutica in Spanish. Gastelurrutia 
[34] also discusses the problem of translating from English into Spanish and pro-
poses that the original term (Pharmaceutical Care) should be maintained so that 
it does not lose its meaning. The question arises whether PC is focused on the 
pharmaceutical product or the patient.
– In the practice of PCA, there is a predominance of the administrative-mana-
gerial-technological perspective in the provision of health services above the 
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humanistic-educational-legislative perspective, without consideration of the 
paradigmatic due to it is not being under discussion for the majority of research-
ers, legislators, and administrators.
The second aspect of analyzing is related to the ideology of care, so it is necessary to dis-
cuss the interpretation of the word atención/cuidado (care) and its subsequent imple-
mentation in the identification of needs, problems, and anguish of the patient. For this 
the following aspects are considered:
– The meaning of ‘care’ when translated into Spanish as atención loses its sense of 
integrality, horizontal, symmetrical, participatory relationships, and intersecto-
rality, as well as being interested in something or someone, giving importance, 
caring, or worrying [13].
– According to Cipolle et al. [30], there are two ways of using the word ‘care’ 
(cuidado) in the realization of PC: the first one is considered as the technical 
dimension to care patients that is the guiding axis of care (atención) centered on 
users, where the level of analysis of the user-pharmacist relationship is related 
to the ways of services organization, connecting the clinical dimension with the 
management dimension. The second one is to demonstrate that taking care of a 
patient is to be concerned with the patient’s welfare. An approach that is consis-
tent with what was stated in the Alma-Ata Declaration, the term ‘care’ is under-
stood as the health care task that goes beyond care (atención) [13, 30]. The use of 
this word in the care process is an advance in the realization of the practice of PC, 
since it takes into account the needs, culture, environment, and commitment to 
the patient’s welfare, although implicitly reflects the lack of patient autonomy.
– Care (cuidado) can also be understood as the non-formal health practices (pre-
ventive or curative) performed by people outside the health system. According 
to this, care can be developed individually (self-care: diets and physical exercise) 
or care by other caregivers. From Latin American social medicine and collective 
health approach or perspective, it has been argued that this meaning brings up 
a risk for the individuals and families, as being held responsible for caring or 
neglecting their health, thus individualizing and privatizing this function, dis-
connecting it from its historical, political, economic, and collective construction 
dimensions, and exempting the States in their responsibility of caring for people 
[13, 35].
–  Care from the bonding-affective approach, used by the professional nursing, 
involves not only the patient care tasks but also a tacit work of emotional attach-
ment to the patient [13]. The nursing profession has developed at least three 
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models of care: naturalistic, substitutive or helping, and interrelated [36]. This 
aspect, not yet explored, could be useful in the practice of pharmaceutical care.
Two groups of authors identify two ideologies. They agree with one, the PCC; how-
ever, they differ in the other ideology. Bjorkman et al. [20] propose the EBM approach, 
while Cipolle [30] suggests the product-centered approach. As mentioned above, PC 
can be performed either using EBM or the PCC as a care ideology. From the results 
of this review, it was found that in neither case, the patient was the center of attention 
and apparently the EBM is used to propose a solution to their needs. EBM is the most 
direct and aggressive way to consolidate the hegemonic medical model (HMM) [37] 
because it eliminates the social context, isolates prejudices, ideologies, and preconcep-
tions that may affect the objective interpretation of results and leaves out everything 
that does not have scientific evidence. However, the prescription is not objective and 
free of values, but it is socially and culturally determined because it is based on personal 
interactions with the pharmaceutical industry representatives, colleagues, and opinion 
leaders [38]. Under this approach, health care professionals search for scientific evi-
dence of the interventions that could be used, leaving aside the needs and expectations 
of the patients. The PCC supposes a change in the way of thinking of the healthcare 
professional (especially the physician) because he has to surrender his absolute control 
and give power to the patient. The PCC will allow a pharmaceutical-patient relation-
ship (PPR) in which responsibility is shared and an alliance that promotes the patient’s 
health is generated [39]. 
Construction of the knowledge object (PCAs)
In the construction of the knowledge object, the following activities, among others, 
were taken into account:
Recognition of the problem of drug use: 23.3% (20/86) of SR/MA used the term drugs-
related problem (DRP). Of these, 60% (12/20) referred to the classification proposed 
by Strand; the rest did not reference any author. Because there is no unit of judgment 
regarding the DRPs classification, some of them are mentioned without their being in 
a particular classification: 23.3% of the reviews identified that the problem of drug use 
was related to clinical aspects (adherence, interactions, adverse reactions), administra-
tive (errors in dispensing, lack of access), and in some cases economic (therapy cost).
Identification of the causes of the drug problem: 67% (58/86) of the reviews identified 
the causes, which were related to the patients in a 34.5% (20/58), with prescribers in 
55.1% (32/58). Other causes such as the care load, lack of capacity of the institution, 
informal prescribers, and pharmaceutical promotion represented 10.4% (6/58). In 
general terms, 25% of the reviews identified a lack of knowledge and skills as a cause of 
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inadequate medicines uses, 15% lack of independent information, 1% non-restrictive 
availability of medicine, and excessive work of health professionals. Lack of access to 
medications, inadequate promotion, and profit sales was not identified in the reviews.
It seems that the identification of problem associated with the drug use is the central 
axis of the pharmacist’s care activity, which is done according to the literature con-
sulted through the DRP. However, this term or some of its equivalents (Medication 
Related Problem, Drug-Related Problem) are far from being universally accepted. 
Some authors have found up to 14 different classifications, some of which have no defi-
nition or have not been validated [40-42]. On other cases, it has also been used in the 
context of pharmacovigilance, not only in its definition but as a system for classifying 
adverse drug reactions [43, 44].
The results of this review show that only a deficient number of reviews use the term 
DRP and in almost all cases they refer to Strand et al. Also, it can be identified in all of 
them that these DRPs are related to biological aspects (not control of a disease, insuf-
ficient or excessive doses, adverse reactions, etc.), administrative aspects (inadequate 
dispensing, no medication availability, lack of controls, lack of information, etc.), com-
municative aspects (lack of information, communication, education, etc.), and only 
in the case of PCNE explicitly recognize economic problems (the medicine is more 
expensive than necessary) [32, 42]. 
Although Hepler [4] firmly insisted that PC constituted a paradigm change where the 
pharmacist activities were now focused on the patient rather than on the medicine; 
the definition and classification of DRPs dealt a severe blow to this claim, since its 
construction is based on the product (interactions, adherence to the medicine, lower 
doses, adverse reactions, etc.) Despite the individual efforts to show the identification 
of DRPs from the patient’s point of view, the other needs (according to Maslow) that 
contribute to the current health situation are not discussed or considered [45]. DRPs 
are conceptual and theoretical constructions of pharmacists where patients’ participa-
tion has not been taken into account, with some exceptions [46], and the pharma-
cists do not consider that most of the identified DRPs are not the responsibility of the 
patient. An individual identification and intervention are made without taking into 
account the social, cultural, and economic context in which the patient lives. These 
findings may mean how deep the positivist paradigm is rooted in the pharmacist’s 
thinking scheme, which partially explains the inconclusive results of the pharmacist 
interventions.
In almost half of the systematic reviews, the authors conclude that it is not possible to 
attribute to the pharmaceutical interventions the observed changes in the evaluated 
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variables, almost always due to methodological reasons. By analyzing the results in this 
way, interventions are being evaluated in terms of HMM (control of biological param-
eters and in the best cases hospitalizations) and the health system management model 
(efficiency in the service provision from the optic of the patient and the provider), 
which is generally related to the increase in expenditure, which puts the financial via-
bility of health systems at risk.
It is evident in this way of constructing the knowledge object that the characteristics of 
the positivist paradigm which confer the ‘objective’ character given by the rules of the 
scientific method, with experimental research, standardized tests, and extensive par-
ticipation of statistics in an improper process, far from the object-subject relationship 
of research-care [47]. The health concept is interpreted as absence of something (lack 
of clinical manifestations or symptomatology). Hence, the pharmacist is recognized as 
an agent that controls the process, verifies the prescriptions, externally and objectively 
manipulates the health status and needs of the patient. In the relationship with the 
patient, the profession is practiced from the vertical relationship, causing the patient 
to act passively, placing his/her trust in the pharmacist’s knowledge, discarding his/her 
knowledge about what happens in his/her body. A change in the paradigm could show 
that DRPs have unknown social causes: discrimination (gender, class, ethnic), social 
stigmatization of certain diseases and medicalization, among others. The medications 
can also be shown as a source of enrichment for particular groups or to be considered 
in its symbolic dimension [35, 48]. 
Some of the explanations for this way of constructing the knowledge object can be 
found in the United States. First with the reform of the faculties of medicine by the 
foundations of John D. Rockefeller and Andrew Carnegie in the years before the 
World War II, and the reformist processes of health systems that began in the 80’s and 
were exported to other countries since the 90’s [49, 50]. These last reforms allowed 
the financial capital introduction in the health sector and, with this, new social actors, 
changes in the sector regulation, and new models of insurance that directly impacted 
the administration and the provision of services. The overwhelming entry of this capi-
tal and its logic in the health sector changed the rules of the game at an economic level, 
introduced changes in individual and collective subjectivities in relation to the health/
illness conception, transformed patients/users into clients/consumers [50], and forced 
the professionals decisions to be subject to those of a system administrators in order to 
ensure efficiency in the delivery of services (health as a real market), through control 
of prescriptions and decisions based on EBM [51]. The pharmaceutical industry took 
advantage of the transformation strategy to customers/consumers and promoted silent 
reforms to reposition itself in the market: it stimulated regulatory changes that allowed 
to impact the medicines and medical technology approval and commercialization, the 
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creation and redefinition of diseases (mongering disease), the modifications in the 
clinical protocols that favor the over-diagnosis, and the mechanisms used to promote 
the demand for procedures and medicines that also justify the high prices that have to 
be paid for them [35, 50]. It is in this scenario that the pharmacist assumes a leading 
role in advocating for the rational use of drugs with an apparently humanitarian objec-
tive (reducing adverse reactions, ensuring therapeutic results, improving the quality of 
life), but with a background eminently economic of a capital accumulation that is in 
dispute: financial capital vs. industrial capital [50].
Methodologies used in the practice of PCAs 
Due to in practically none of the reviews describe the methodology used in the original 
studies, the chosen aspects were analyzed taking into account the people who partici-
pated in the care activity (who and to whom the intervention was performed), and the 
context in which this activity was carried out and the interventions were implemented.
 Actors in the practice of PC: the categories of the personnel that was intervened by the 
pharmacist during the development of the studies were related. In 69.7% (60/86) the 
patient was the only subject of intervention; whereas, the physician was intervened in 
the 1.1% (1/86) of the reviews. The staffgrouping refers to the group of physicians and 
nurses, clarifying that none of the reviews refer to another professional.
Situations in which the pharmacist intervenes: the pharmacist activities can be focused 
on either the person with an illness or the person as a drug consumer. In 59.3% (51/86) 
of the reviews focus the problem of the chronic non-communicable diseases. The 4.6% 
(4/86) was included in the category of “several diseases” since, in the hospital setting, 
patients are hospitalized for complications of their chronic processes or for acute diag-
noses (infections, trauma, cancer), which for their high diversity are very difficult to 
group. 8.1% (7/86) of the reviews were concerned with the use of medication and the 
polymedication.
Interventions: according to the classification proposed by Berimoj [52], Type 2 inter-
ventions (education activities) were the most frequent with 52.3%, followed by Type 
10 interventions (drug therapy follow-up or any other type of follow-up) with a 29%. 
Type 7 and Type 9 interventions (signs and symptoms monitoring, education and sur-
veillance device, respectively) were not performed in any of the studies included in the 
review.
Outcomes: since there are different ways of classifying the evaluated outcomes in the 
literature on this topic, for this study we present the two most recognized ways of 
doing so. According to the proposal of Kozma et al. [53], clinical outcomes are the 
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most frequently evaluated with 83.8%, followed by economic ones with 31.3%, and 
humanistic ones with 27.9%. According to the Benrimoj classification [52], Level III 
outcomes (other indirectly connected variables, pre and post educational tests such as 
medication use, adherence, etc.) with 37.2%, and Level IV outcomes (other variables 
not connected with clinical outcomes such as patient satisfaction, physician satisfac-
tion, etc.) with 34.9%, were the most frequently evaluated. In economic outcomes, all 
studies belonged to Level I and II (minimum cost information, descriptive studies of 
cost). The percentages add more than 100% because the studies can evaluate more than 
one level of outcomes.
For the discussion of the methodology used in the development of the PCA, it can 
be affirmed that all of them have a very similar structure, closely related to the Clini-
cal Method and the Nursing Care Process, which includes the following steps: prob-
lem identification, analysis and evaluation (diagnosis), proposal and implementation 
of solutions, and evaluation of results. The results show a high percentage in which 
only two actors appear: the pharmacist and the patient. Few studies include physicians 
or nurses, much less other health professionals, the state, the pharmaceutical industry, 
insurers, hospitals, employers, among others. Morin insists on using the transdiscipli-
narity to overcome the splitting of knowledge and thus build a totalizing and interact-
ing reality [7]. Although the consulted bibliography emphasizes on the fact that the 
center of attention is the patient, it could not be observed in any of the recovered stud-
ies that the patient was involved as an active or participatory person within the process 
[4, 5]. Another aspect related to the actors is the performance of the pharmacist; since 
for the provision of the PC service requires the development of new knowledge and 
skills; that by not being described, can lead to different conclusions due to a lack of 
homogeneity in these competencies and the practice sites of each study [22, 54].
There is a high interest in the intervention of chronic non-communicable diseases 
and problems such as polymedication and the adequate use of medications. Interven-
tions are individual and focused on biological aspects. The outcomes assess the results 
regarding the HMM and the health system management model. Once again a para-
digm of positivism at the service of economic interests is exposed, either as financial 
capital or industrial capital.
The use of classical epidemiology as a research tool leads to an excessive confidence in 
statistics and can lead to results with negative consequences, such as the stigmatization 
of people with some characteristic that is far from ‘normal.’ Mathematics is an exact sci-
ence, but its application to the social sciences is not, because behind every study there 
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are decisions that are influenced by personal, cultural, political, and economic aspects. 
Researchers often forget this limitation and interpret the results of a statistical study 
as if they were the absolute truth. Therefore we make decisions in public health based 
mainly on these results that sometimes find spurious associations. As a consequence, 
it is possible for society or decision-makers to conclude that something has to be done 
to help those who are supposedly affected, stating the beginning of medicalization and 
iatrogenic [55].
The concept of PC was popularized 27 years ago, and it began to develop in the world. 
It seems to be time to reflect on the importance of these health care activities on public 
health and the welfare of people. From the analysis made in this discussion, it seems 
that the pharmacists have dedicated ourselves to reproduce the HMM, because this 
gives us the tranquility of a “scientific” support that seems indisputable, the labor sta-
bility and the social recognition that we have tried to demonstrate since we started to 
venture into this field of pharmacy. It is clear that epistemological changes are required 
to help to construct the knowledge object differently with a methodology that allows 
a realistic approach to the patient and their needs without isolating the social determi-
nants of the health-disease process, and it is also necessary to rethink the ethical basis 
of the PPR in order to contribute to the understanding, interpretation, and explana-
tion of the raised problems. That way may be the primary cause for many SR/MA fail 
to show conclusive results.
Conclusions
A lack of consensus or agreement was identified in the definition of what is and is not 
PC, although it must be recognized an effort to explain the differences and proposed 
agreements in the consulted literature. The literature describes the existence of two 
approaches: technical prescription-focused and humanistic (patient-centered), how-
ever, it was only possible to have evidence of the first one. The construction of the 
knowledge object is based on the positivist paradigm, where DRP is the pharmacist’s 
center of attention, despite there is still no consensus on the different proposals. The 
used methodology shares elements of the Clinical Method and the Nursing Care Pro-
cess, and apparently, with values of the principlism ethics. Interventions, outcomes, 
and results are supported by the HMM and the studies in classical epidemiology that 
reproduces this way of understanding health-disease-care, where the social, economic, 
and political aspects related to medicine are invisible.
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